Open AccessImatinib for the Treatment of Pulmonary Arterial Hypertension and Pulmonary Capillary Hemangiomatosis
Author(s) -
Nayyar Dhruv,
Muthiah Kavitha,
Kumarasinghe Gayathri,
Hettiarachchi Ravin,
Celermajer David,
Kotlyar Eugene,
Keogh Anne
Publication year - 2014
Publication title -
pulmonary circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.791
H-Index - 40
ISSN - 2045-8940
DOI - 10.1086/675996
Subject(s) - medicine , imatinib , pulmonary hypertension , pathogenesis , imatinib mesylate , platelet derived growth factor receptor , cardiology , receptor , growth factor , myeloid leukemia
Despite currently available treatments, the prognoses of pulmonary arterial hypertension (PAH) and pulmonary capillary hemangiomatosis (PCH) remain poor. Platelet‐derived growth factor and its receptor (PDGFR) have been implicated in the pathogenesis of pulmonary hypertension in PAH and PCH. Imatinib, a PDGFR antagonist, may be beneficial in the treatment of both conditions because of its potent antiproliferative effect. We report two cases that demonstrate the potential for safe and efficacious use of imatinib in PAH and PCH.